

MPAC meeting 16-18 September 2015

Declaration of Interests

All MPAC members participating in the meeting updated their declaration of interest, which was assessed by the WHO Secretariat.

Nine members reported relevant interests, which are summarized below.

Of note, three MPAC members in attendance at this particular meeting (Brian Greenwood, Kevin Marsh, Laurence Slutsker) have declared their involvement in the RTS,S Phase 3 trial. They will be allowed to participate in the update on the RTS,S vaccine (Session 8 of the meeting) as it is for discussion, and not for decision. However, they will be recused during the part of the session on 18 September where potential draft recommendations are discussed. MPAC members with a personal, specific, or financially significant interest in the RTS,S vaccine will have no involvement in decision-making related to policy for RTS,S. The same holds true for other meeting agenda items as well. Therefore:

One MPAC member (Nick White) whose research institution receive significant funding related to Mass Drug Administration will be recused from Session 1 (recommendations from the Evidence Review Group on Mass Drug Administration) as the session is for decision.

One MPAC member (Brian Greenwood) whose research institution receive significant funding related to Intermittent Screening and Treatment of malaria in pregnancy will be recused from Session 4 (recommendations from the Evidence Review Group on malaria in pregnancy) as the session is for decision.

All reported relevant interests by MPAC members are summarized below:

Fred Binka

Receives research support from the Bill & Melinda Gates Foundation (BMGF) for the InDepth Network Effectiveness and Safety Studies (INESS) related to the safety and effectiveness of malaria drugs. This interest was assessed as non-personal, non-specific and financially significant*.

Patricia Graves

Receives consultancy fees from WHO and UCSF to review malaria and vector-borne disease programmes. This interest was assessed as personal, non-specific, and financially significant*.

Brian Greenwood

Receives research funding from the Malaria Vaccine Initiative (MVI) for the RTS,S vaccine trial and from EDCTP to support the evaluation of interventions to control malaria in pregnancy. This interest was assessed as non-personal, specific, and financially significant*.

Rose Leke

Receives funding from Pfizer and the National Institute of Allergy and Infectious Diseases (NIAID), USA for research on the impact of Intermittent Preventive Treatment in pregnancy on specific antibody levels. This interest was assessed as non-personal, non-specific and financially significant*.

Kevin Marsh

Is on the malaria vaccines advisory group for USAID, is a PI on the Phase 3 RTS,S study and a collaborator on a Phase 2 malaria vaccine study. This interest was assessed as non-personal, specific, and financially significant*.

Sylvia Meek

Is technical director of the Malaria Consortium which receives research funding from the Bill & Melinda Gates Foundation, DfID, and CDC. This interest was assessed as being non-personal, non-specific, and financially significant*.

Laurence Slutsker

Receives research support from MVI. This interest was assessed as personal, specific and not financially significant*.

Neena Valecha

Directs the National Institute of Malaria Research - New Delhi, which receives research funding from the company Bestnet. This interest was assessed to be non-personal, non-specific and financially significant*.

Nick White

Receives support from the Wellcome Trust and BMGF for research on Mass Drug Administration. This interest was assessed as non-personal, specific and financially significant*. In addition he receives funding from Wellcome Trust, MMV, BMGF, UKAID, Novartis, GSK, Holley-Cotec and DNDi for research related to anti-malarial drugs. This interest was assessed as non-personal, non-specific and financially significant*.

*According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1,000 USD would also constitute a "significant shareholding".

Last updated: 15 September 2015